Treatment-resistant depression stories

Jul 31, 2026

MD Anderson researchers identify shared neuroimmune mechanisms in rapid-acting antidepressants

Scientists at The University of Texas MD Anderson Cancer Center have discovered common neuroimmune signatures that may explain how rapid-acting antidepressants like ketamine and psychedelics work to reduce symptoms in treatment-resistant depression.

Jul 31, 2026·1 source

Jul 7, 2026

Compass Pathways' Psilocybin Therapy Shows Durable Benefits for Treatment-Resistant Depression in Pivotal Trial

Compass Pathways reported results from a pivotal study showing its psilocybin-based therapy demonstrated long-lasting benefits for treatment-resistant depression, though investor reaction was mixed as shares fell nearly 10% on the data.

Jul 7, 2026·2 sources

Top claims

▪Future research will determine whether IL-15, IL-7, and related biomarkers can predict treatment response before therapy.
▪Rapid-acting antidepressants can reduce symptoms in difficult-to-treat depression and may help identify patients most likely to benefit from these treatments.
▪Participants who responded to ketamine showed lower IL-15 pathway activity and higher B cell signaling before treatment than nonresponders.

Subtopics

Mental health Depression Ketamine Psychedelic clinical research & trials Psychedelic assisted therapy

Psilocybin

Related timelines

Treatment-resistant depression stories

MD Anderson researchers identify shared neuroimmune mechanisms in rapid-acting antidepressants

Compass Pathways' Psilocybin Therapy Shows Durable Benefits for Treatment-Resistant Depression in Pivotal Trial

Related timelines

Iran War

US Congress

Venture capital funding

Strait of Hormuz blockage

Trump administration